KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Current Leases: 2017-2025

Historic Current Leases for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $8.0 million.

  • Amneal Pharmaceuticals' Current Leases fell 17.70% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 17.70%. This contributed to the annual value of $9.4 million for FY2024, which is 2.48% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Current Leases stood at $8.0 million for Q3 2025, which was down 2.89% from $8.2 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Current Leases ranged from a high of $10.3 million in Q3 2022 and a low of $6.6 million during Q1 2021.
  • For the 3-year period, Amneal Pharmaceuticals' Current Leases averaged around $9.2 million, with its median value being $9.4 million (2024).
  • Examining YoY changes over the last 5 years, Amneal Pharmaceuticals' Current Leases showed a top increase of 49.61% in 2021 and a maximum decrease of 45.26% in 2021.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Current Leases stood at $9.7 million in 2021, then decreased by 14.09% to $8.3 million in 2022, then grew by 10.65% to $9.2 million in 2023, then increased by 2.48% to $9.4 million in 2024, then fell by 17.70% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $8.2 million for Q2 2025, and $9.0 million during Q1 2025.